Investorsยท2025-11-04 21:17Core Insights - Hims & Hers Health reported $599 million in sales for Q3, exceeding expectations of $582 million and its own guidance of $570 million to $590 million, but earnings per share were only 6 cents, missing forecasts by 3 cents [1][3] - The company tightened its full-year sales outlook to $2.34 billion to $2.36 billion, indicating a year-over-year growth of 58.1% to 59.5%, but Q4 guidance was lower than expected at $605 million to $625 million, compared to the Street's projection of $632 million [3][4] - The potential partnership with Novo Nordisk could enhance revenue opportunities for Hims, particularly in the weight loss vertical, which is a key growth driver for the company [5][7] Financial Performance - Hims & Hers achieved Q3 sales of $599 million, surpassing both market expectations and internal guidance [1] - The company expects full-year sales to be between $2.34 billion and $2.36 billion, a slight adjustment from previous guidance [3] - Q4 sales guidance is projected at $605 million to $625 million, falling short of analyst expectations [2][3] Market Reaction - Following the earnings report, Hims stock rose over 5% to $46.83, reflecting investor optimism despite mixed results [2] - The stock remains volatile, having recently broken out of a cup-with-handle base but subsequently dropping below key moving averages [7] Strategic Developments - Hims is in discussions with Novo Nordisk regarding a potential deal that could clarify uncertainties around their partnership and bolster Hims' weight loss offerings [4][7] - The company has seen a 21% increase in subscribers, reaching 2.5 million, indicating strong adoption of its personalized healthcare platform [6][8] - New verticals, including testosterone offerings and menopause care, are being launched, expanding Hims' total addressable market [8]